Investment Thesis for Gilead Sciences, Inc. (NYSE: GILD)
Embargo until
Date
2016-07
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Institute for Applied Economics, Global Health, and the Study of Business Enterprise
Abstract
This working paper is an in-depth analysis of Gilead Sciences, Inc. Our analysis examines the economic factors that impact Gilead’s underlying business and how the firm has adapted to these ever-changing factors. This economic analysis is then combined with our proprietary, Hanke-Guttridge Discounted Cash Flow (HG-DCF) model to determine Gilead’s financial position. The HG-DCF model will be presented along-side Monte-Carlo simulations to reveal the distribution of probable free cash flows, the likelihood of future earnings, and the degree to which the firm’s drug pipeline is being considered by the current market valuation. In addition to these quantitative factors, we also examine the compensation plans of Gilead’s executives to assess alignment with shareholders. At the conclusion of this analysis, it is our intention for readers to understand Gilead’s business plan and the company’s financial standing to arrive at a sound investment decision.
Description
The Studies in Applied Finance series is under the general direction of Prof. Steve H. Hanke, Co-Director of the Johns Hopkins Institute for Applied Economics, Global Health, and Study of Business Enterprise (hanke@jhu.edu) and Dr. Hesam Motlagh (hesamnmotlagh@gmail.com), a Fellow at the Johns Hopkins Institute for Applied Economics, Global Health, and Study of Business Enterprise.
This working paper is one in a series on applied financial economics, which focuses on company valuations. The authors are mainly students at the Johns Hopkins University in Baltimore who have conducted their work at the Institute as undergraduate researchers.
Keywords
finance, investment thesis, Gilead Sciences, financial modeling, discounted cash flow, free cash flow, Monte-Carlo simulation, management compensation